Local Antibiotic Delivery Systems

Definition

Why Local Delivery is Needed

• Avascular/sclerotic bone around infection resists systemic antibiotic penetration
• Biofilm-producing organisms require concentrations 100–1000× higher than systemic routes can safely achieve
• Dead space after surgical debridement provides a nidus for re-infection unless obliterated
• Systemic routes carry dose-dependent toxicity (nephrotoxicity with aminoglycosides, ototoxicity, etc.)

Types / Classification

1. Non-Biodegradable (Non-Absorbable) Systems

• Achieves very high local concentrations with minimal systemic levels
• Excellent structural/space-filling properties
• 40+ years of clinical experience
• Can be combined with implant stabilisation

• Must be surgically removed (if left in situ, provides a substratum for bacterial colonisation — "foreign body effect")
• Inefficient release kinetics for some drugs (vancomycin: burst only → subtherapeutic tail)
• Incompatible with certain antibiotics (tetracycline, rifampicin)
• Requires a second operative procedure for removal
• Increased cost and surgical morbidity

2. Biodegradable (Bioabsorbable) Systems

A. Natural Polymers (Protein-Based)

B. Bone Graft Substitutes / Bioceramic Materials

C. Synthetic Polymers

• Obliterate dead space AND release antibiotic after degradation
• Leave no residual substratum for bacterial colonisation
• Can carry a wider range of antibiotics
• Require fewer subsequent surgeries (no removal needed)
• Osteoconductive materials simultaneously promote bone healing

Applications

Summary of Advantages vs. Disadvantages

Key Structural Principle

1. Biocompatibility — tolerated by host tissues without reaction
2. Adequate release kinetics — maintain antibiotic concentrations above MIC (minimum inhibitory concentration) at the infection site throughout the therapeutic window
3. Dead space management — physically fill the void left by debridement to prevent fluid accumulation and re-infection

The Bone–Brain Axis

1. Definition

• Bone-derived hormones/factors entering the bloodstream and crossing the blood–brain barrier (BBB)
• Hypothalamic neuropeptides, neurotransmitters, and sympathetic/parasympathetic signals acting on osteoblasts and osteoclasts
• Extracellular vesicles (EVs) carrying miRNAs and proteins between the two systems

"The bone and brain, though distinct in structure and function, share remarkable molecular and developmental similarities." — Hansda & Das, Biology 2025 [PMID 41007423]

2. Illustrative Diagrams

Diagram 1 — Bone–Organ Axes (including Bone–Brain Axis)

Diagram 2 — Bone-Derived Proteins Crossing the Blood–Brain Barrier

Diagram 3 — Brain–Bone Neural Regulation

3. Components / Key Players

A. Bone → Brain Signals (Bone-Derived Factors)

B. Brain → Bone Signals (Neural/Neuroendocrine Factors)

4. Types of Bone–Brain Axis Communication

Type 1: Endocrine (Hormonal) Communication

• Bone-derived hormones (OCN, LCN2, FGF-23) enter systemic circulation → cross BBB → bind CNS receptors
• Most studied pathway; OCN is the principal "bone hormone" acting on the brain

Type 2: Neural (Autonomic) Communication

• Sympathetic: hypothalamus → lateral hypothalamic area → spinal cord → sympathetic chain → β2-adrenergic receptors on osteoblasts → ↑ RANKL, ↓ OPG → net resorption
• Parasympathetic: vagal and local cholinergic innervation → muscarinic receptors → ↑ bone formation
• Sensory/Nociceptive: sensory nerves in bone (substance P, CGRP) send pain/stress signals to the brain; important in fracture pain and bone disease

Type 3: Immune-Mediated (Osteoimmune) Communication

• Bone marrow is a primary immune organ; immune cells (macrophages, T/B cells) regulate osteoclast differentiation via RANKL/OPG system
• Brain neuroinflammation (microglia activation, IL-1β, TNF-α, IL-6) affects bone remodelling via HPA axis and direct circulating cytokines

Type 4: Extracellular Vesicle (EV) Communication

• Bone marrow mesenchymal stem cells and osteoblasts release EVs containing miRNAs (miR-21, miR-124-3p, miR-138-5p) that cross the BBB and regulate neuroplasticity, neuroinflammation, and glial function
• Brain-derived EVs also carry miRNAs that influence osteogenesis

Type 5: Shared Molecular Pathway Communication

• Wnt/β-catenin: active in both osteoblasts and neurons; sclerostin (a Wnt inhibitor from bone) can cross BBB
• RANKL/NF-κB: regulates both osteoclastogenesis and microglial activation
• Leptin–melanocortin system: integrates energy metabolism, bone mass, and brain reward circuits

5. Applications / Clinical Significance

6. Disadvantages / Limitations / Challenges

7. Key Signalling Pathways Summary

BONE SIDE                    ←→                    BRAIN SIDE
─────────────────────────────────────────────────────────────
Osteocalcin (OCN) ──────────────────▶ GPR158/GPRC6A
                                       ↓
                                   Gαq → IP₃ → BDNF
                                       ↓
                               ↑ Serotonin, Dopamine
                               ↓ GABA → Anxiolytic + Cognitive ↑

LCN2 ───────────────────────────────▶ MC4R (hypothalamus)
                                       ↓ cAMP ↑
                               ↓ Appetite, ↑ BDNF/CRH

FGF-23 ─────────────────────────────▶ FGFR1 in brain
                               Phosphate/Vit D homeostasis

Sympathetic NS ◀──────────── Lateral hypothalamus (leptin, NPY)
(β2-AR on osteoblasts)
↑ RANKL → ↑ Osteoclastogenesis → Net Bone Loss

Wnt/β-catenin ←────────────────────── Sclerostin (SOST from osteocytes)
(shared pathway in neurons and osteoblasts)

8. Summary Table

• Shi & Chen, Eur J Med Res 2024 — [PMID 38849920]
• Hansda & Das, Biology 2025 — [PMID 41007423]
• Guan et al., Biology 2025 — [PMID 41007258]
• Chen et al., Neuroscience 2026 — [PMID 41391736]
• Li et al., Front Cell Dev Biol 2025 — [PMID 40337551]
• Lee et al., Curr Osteoporos Rep 2026 — [PMID 41663782]
• Kang et al., Front Pharmacol 2025 — [PMID 40727110]